These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 29998882)

  • 1. Efficacy of Pegylated Interferon Monotherapy versus Sequential Therapy of Entecavir and Pegylated Interferon in Hepatitis B e Antigen-Positive Hepatitis B Patients: A Randomized, Multicenter, Phase IIIb Open-Label Study (POTENT Study).
    Jun DW; Ahn SB; Kim TY; Sohn JH; Kim SG; Lee SW; Kim BH; Kim DJ; Kim JK; Kim HS; Hwang SG; Choi WC; Tak WY; Lee HJ; Yoon KT; Yun BC; Lee SW; Baik SK; Park SH; Park JW; Park SJ; Lee JS
    Chin Med J (Engl); 2018 Jul; 131(14):1645-1651. PubMed ID: 29998882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, open-label clinical study of combined pegylated interferon Alfa-2a (40KD) and entecavir treatment for hepatitis B "e" antigen-positive chronic hepatitis B.
    Xie Q; Zhou H; Bai X; Wu S; Chen JJ; Sheng J; Xie Y; Chen C; Chan HL; Zhao M
    Clin Infect Dis; 2014 Dec; 59(12):1714-23. PubMed ID: 25190434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase IV randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B.
    Hsu CW; Su WW; Lee CM; Peng CY; Chuang WL; Kao JH; Chu HC; Huang YH; Chien RN; Liaw YF
    J Formos Med Assoc; 2018 Jul; 117(7):588-597. PubMed ID: 29456079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy: An open-labelled, randomized, controlled, "real-life" trial.
    Luo XD; Chen XF; Zhou Y; Chen XP
    J Viral Hepat; 2017 Nov; 24 Suppl 1():36-42. PubMed ID: 29082651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy of 104-week sequential therapy with telbivudine or entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24-week therapy with pegylated interferon-α-2a].
    Luo XD; Chen XP; Chen R; Chen XF; Huang J
    Zhonghua Gan Zang Bing Za Zhi; 2016 Apr; 24(4):241-5. PubMed ID: 27470620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [HBeAg seroconversion achieved by sequential peginterferon alfa-2a therapy in chronic hepatitis B patients with unsatisfactory end point following entecavir treatment].
    Chen XF; Chen XP; Ma XJ; Chen WL; Luo XD; Liao JY
    Zhonghua Gan Zang Bing Za Zhi; 2013 Jul; 21(7):502-5. PubMed ID: 24074707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment.
    Li GJ; Yu YQ; Chen SL; Fan P; Shao LY; Chen JZ; Li CS; Yi B; Chen WC; Xie SY; Mao XN; Zou HH; Zhang WH
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4121-8. PubMed ID: 25941216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
    He LT; Ye XG; Zhou XY
    World J Gastroenterol; 2016 Dec; 22(46):10210-10218. PubMed ID: 28028369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: A multicenter randomized trial (ARES study).
    Brouwer WP; Xie Q; Sonneveld MJ; Zhang N; Zhang Q; Tabak F; Streinu-Cercel A; Wang JY; Idilman R; Reesink HW; Diculescu M; Simon K; Voiculescu M; Akdogan M; Mazur W; Reijnders JG; Verhey E; Hansen BE; Janssen HL;
    Hepatology; 2015 May; 61(5):1512-22. PubMed ID: 25348661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B.
    Boglione L; Cariti G; Di Perri G; D'Avolio A
    J Med Virol; 2016 Nov; 88(11):1953-9. PubMed ID: 27017932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial).
    Ning Q; Han M; Sun Y; Jiang J; Tan D; Hou J; Tang H; Sheng J; Zhao M
    J Hepatol; 2014 Oct; 61(4):777-84. PubMed ID: 24915612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Entecavir add-on Peg-interferon therapy plays a positive role in reversing hepatic fibrosis in treatment-naïve chronic hepatitis B patients: a prospective and randomized controlled trial.
    Yang JM; Chen LP; Wang YJ; Lyu B; Zhao H; Shang ZY; Li J; Fan ZY; Wu SD; Ming X; Li X; Huang SP; Cheng JL
    Chin Med J (Engl); 2020 Jul; 133(14):1639-1648. PubMed ID: 32568867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients.
    Zheng MH; Shi KQ; Dai ZJ; Ye C; Chen YP
    Clin Ther; 2010 Apr; 32(4):649-58. PubMed ID: 20435234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of fibrosis regression of entecavir alone or combined with pegylated interferon alpha2a in patients with chronic hepatitis B.
    Chen S; Zhou J; Wu X; Meng T; Wang B; Liu H; Wang T; Zhao X; Kong Y; Wu S; Ou X; Jia J; Sun Y; You H
    Hepatol Int; 2021 Jun; 15(3):611-620. PubMed ID: 33677771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Optimal treatment regimen for patients with HBeAg-positive chronic hepatitis B after suboptimal response to 24 weeks of Peg-IFN α-2a].
    Luo XD; Chen XP; Chen XF
    Zhonghua Gan Zang Bing Za Zhi; 2017 Dec; 25(12):896-901. PubMed ID: 29325289
    [No Abstract]   [Full Text] [Related]  

  • 17. Pegylated Interferon Alfa-2b Add-on Treatment in Hepatitis B Virus Envelope Antigen-Positive Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogue: A Randomized, Controlled Trial (PEGON).
    Chi H; Hansen BE; Guo S; Zhang NP; Qi X; Chen L; Guo Q; Arends P; Wang JY; Verhey E; de Knegt RJ; Xie Q; Janssen HLA
    J Infect Dis; 2017 Apr; 215(7):1085-1093. PubMed ID: 28329061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study.
    Huang Z; Deng H; Zhao Q; Zheng Y; Peng L; Lin C; Zhao Z; Gao Z
    Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1165-9. PubMed ID: 23571612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B.
    Liem KS; van Campenhout MJH; Xie Q; Brouwer WP; Chi H; Qi X; Chen L; Tabak F; Hansen BE; Janssen HLA
    Aliment Pharmacol Ther; 2019 Feb; 49(4):448-456. PubMed ID: 30689258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Analysis of the factors for predicting the outcomes of interferon-α and entecavir treatments for chronic hepatitis B with positive HBeAg].
    Xie Z; Zhou F; Zhou Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2013 Jun; 33(6):878-81. PubMed ID: 23803202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.